Top Markets
Coin of the day
HLS Therapeutics Inc. HLS Therapeutics Inc.

HLS Therapeutics Inc.

HLS
Rankning i aktier #22602
HLS Therapeutics Inc. operates as a specialized pharmaceutical firm,... HLS Therapeutics Inc. operates as a specialized pharmaceutical firm, concentrating on the acquisition and commercialization of medicinal products, primarily within the niche central nervous system (CNS) and cardiovascular (CV) sectors. Its reach extends across Canada, the United States, and international markets. The company's core product lineup includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsule formulation; and PERSERIS, an injectable risperidone product for treating schizophrenia. Additionally, HLS offers MyCare psychiatry laboratory assays and MyCare Insite tests for point-of-care therapeutic drug-level monitoring. Furthermore, the company possesses U.S. marketing privileges for Absorica, a commercial-stage dermatology solution, and Canadian rights for Trinomia, a cardiovascular therapeutic. It also manages a portfolio of royalty interests from four distinct healthcare products. Founded in 2018, HLS Therapeutics Inc. is based in Etobicoke, Canada.
Aktiekurs
$2.75
Senast synkroniserad: 2026-08-21
Marknadsvärde
$86.08M
Förändring (1 dag)
-3.85%
Förändring (1 år)
-27.06%
Land
CA
Handel HLS Therapeutics Inc. (HLS)

Kategori

P/B-tal för HLS Therapeutics Inc. (HLS)
P/B-tal per 2026 TTM: 0
Enligt HLS Therapeutics Inc. senaste finansiella rapporter och aktiekurs är det aktuella P/B-talet (TTM) 0. I slutet av 2026 hade företaget ett P/B-tal på 0.
Historik för P/B-tal för HLS Therapeutics Inc. från 2026 till 2026
P/B-tal vid årets slut
År P/B-tal Ändra
Inte tillräckligt med data för de angivna datumen.
P/B-tal för liknande företag eller konkurrenter